Turn Therapeutics Inc. (TTRX)
Health Care · biotechnology · NASDAQ
Turn Therapeutics is a clinical-stage biotechnology company developing GX-03, a non-systemic topical immunomodulator targeting atopic dermatitis and other inflammatory skin conditions.
What Turn Therapeutics Inc. does
Turn Therapeutics is a clinical-stage biotechnology company focused on developing non-systemic, topical immunomodulators for inflammatory skin diseases. Its lead drug candidate, GX-03, is currently in an adaptive Phase 2 clinical trial for the treatment of atopic dermatitis (eczema) and is being advanced for other indications including onychomycosis and hidradenitis suppurativa. The company also maintains a legacy portfolio of cleared medical device formulations for wound and dermatitis management, which it licenses to commercial partners.
Recent developments
In August 2026, the company expanded its Phase 2 study of GX-03 for atopic dermatitis following positive interim data and appointed Dr. Stephen M. Hahn as Executive Clinical and Regulatory Lead. Additionally, the company announced plans to expand the pipeline into hidradenitis suppurativa.
From Turn Therapeutics Inc.'s filing of 2026-08-12.
Themes: atopic dermatitis / eczema, dermatology drug development, topical therapies, inflammatory diseases, onychomycosis, hidradenitis suppurativa
Fundamentals
- Price$10.15 as of 2026-10-21 close
- Market cap$302M as of 2026-08-12 (share count; price 2026-10-21)
- 1-year return+114.1% 2025-10-21 close $4.74 → 2026-10-21 close $10.15
- P/En/a negative earnings
- ROE-68.2% FY2025, SEC XBRL
- ROICn/a No figure: its 10-K tags no pre-tax income, so no tax rate can be taken.
- Debt / equity8.83 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Beta1.15 as of 2026-09-02
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How TTRX compares in its sector
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-02
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Operating income | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | -$2M | -$6M | -$0.20 | -$923364† |
| Q1 FY2026 2026-03-31 | -$1M | -$970972 | -$0.03 | -$2M |
| Q4 FY2025 2025-12-31 | -$2M† | $279070† | $0.01† | -$1M† |
| Q3 FY2025 2025-09-30 | -$2M | -$2M | -$0.07 | -$588610† |
| Q2 FY2025 2025-06-30 | -$1M | -$1M | -$0.05 | -$499966† |
| Q1 FY2025 2025-03-31 | -$384997 | -$328547 | -$0.01 | -$298058 |
| Q4 FY2024 2024-12-31 | -$328957† | -$323130† | -$0.02† | -$430545† |
| Q3 FY2024 2024-09-30 | -$672992 | -$666442 | -$0.03 | — |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$10M
- Total debt$6M borrowings only; leases excluded
- Net debt-$4M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How Turn Therapeutics Inc. looks technically
Turn Therapeutics Inc. (TTRX) is trading 51.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average has held above its 200-day average for at least 52 trading days — a long-sustained "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day low, its first since 2026-09-04, breaking below its recent trading range. It is 61.7% below its highest point of the past year. Trading volume is unusually light — only about 42% of its 30-day average.
Trend
7
| Distance from the 200-day | it is trading 51.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +51.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $11.63 | $11.63 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $6.69 | $6.69 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Since the 50/200 cross | its 50-day average has held above its 200-day average for at least 52 trading days — a long-sustained "golden cross", a bullish long-term signal | at least 52 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend) | 15.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30) | 39.5 |
|---|---|---|
| Position in its 14-day range | it is trading right at the bottom of its 14-day range ($10.14 to $13.48) — its "stochastic" reading is 0 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 0.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 19 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $26.50 | $26.50 |
|---|---|---|
| From the 52-week high | it is 61.7% below its 52-week high (its highest price of the past year) | -61.7% |
| Above the 52-week low | it is 294.9% above its 52-week low (its lowest price of the past year) | +294.9% |
| Below the 52-week high | it is 61.7% below its highest point of the past year | 61.7% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-09-04, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day high about 23 trading days ago | 23 sessions |
| All-time high | its highest closing price on record is $26.50 (set on 2025-10-09) | $26.50 |
| Given back of the 52-week move | over the past year its closes ranged ($2.71 to $15.34), and it has given back roughly a third of its rise from last year’s low — 41% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $7.13 to $7.53. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 41.1% |
| From the all-time high | it is 61.7% below its all-time high | -61.7% |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $2.57 (set on 2025-11-20) | $2.57 |
| Above the all-time low | it is 294.9% above its all-time low | +294.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 49th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.03 between its high and its low — about 10.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.03 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $9.60 and $14.31 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $9.60 – $11.95 – $14.31 |
| Typical daily range (% of price) | its price moves about 10.2% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 10.2% |
| Stretch from the 200-day average | it is trading 3.4 daily ranges above its 200-day average price (51.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 42% of its 30-day average | 0.42× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|---|---|
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-21 1.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.3% |
|---|---|---|
| Open gap | it gapped 2.3% below the previous close 7 sessions ago and has not traded back through the level it left behind at 12 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.3% |
| Gap filled | a 2.3% gap down opened on 2026-10-15 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 4 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -5.49% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 33.8 percentage points (the stock lost 33.8% while the market lost 0.1%) | -33.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 3.6 percentage points (the stock lost 0.3% while the market gained 3.3%) | -3.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 193.2 percentage points (the stock gained 203.0% while the market gained 9.8%) | +193.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 99.0 percentage points (the stock gained 114.1% while the market gained 15.2%) | +99.0% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 4.3% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 10.7% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -4.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 8% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $9.39 — a volume-weighted average of daily closes over 192 sessions, not a true tick-by-tick VWAP. | +8.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 20% below the average price paid since it last reported on 2026-08-12 (its 10-Q), so the typical buyer over that stretch is under water. That average is $12.69 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -20.0% |
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · trendless / choppy (low ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$25.00 range $24.00 – $26.00
Analyst estimates, as of 2026-10-20. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["History of operating losses and dependence on additional financing to fund clinical development; substantial doubt about ability to continue as a going concern.","Clinical development is expensive and subject to failure or regulatory delays; drug candidates may never receive FDA approval.","Reliance on a single lead product candidate (GX-03) and limited internal resources."]
What changed in the latest 10-Q
AI-assisted comparison of TTRX's 10-Q filed 2026-05-11 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- In newer filing: Reference to Annual Report on Form 10-K for year ended December 31, 2025, filed March 31, 2026 (replacing prospectus reference)
- In newer filing: Specific mention of interim assessment at approximately 50% trial completion with topline results expected mid-2026
- In newer filing: Description of Independent Interim Assessment Committee (IAC) powers including pre-written statements on conditional probability and ability to increase enrollment up to 200%
- In newer filing: Statement that adaptive trial design does not impact statistical significance because interim assessment committee is fully independent
- In newer filing: Description of GX-03 in-vivo studies demonstrating nail-plate penetration and significant reduction of fungal burden for onychomycosis
- In newer filing: Explicit statement that K183681 has recently been licensed to Medline Industries, LP under a license and supply agreement
- In newer filing: Cash position as of March 31, 2026 of approximately $11.22 million (versus $5.08 million at December 31, 2025)
- In newer filing: Funding runway extended to first quarter of 2027
- Removed:
- In older filing: Detailed description of PermaFusion platform technology and proprietary mixing process
- In older filing: Reference to Hexagen formulation and founder's personal journey developing topical ointment
- In older filing: Discussion of three FDA clearances for historical formula and extensive human utilization
- In older filing: Detailed description of intranasal vaccine partnership with global nonprofit organization and cold-storage benefits
- In older filing: Preclinical xenograft studies results for herpes zoster ophthalmicus (85% viral load reduction) and basal cell carcinoma (29% and 20% tumor reduction comparisons)
- In older filing: Reference to prospectus filed October 8, 2025
- In older filing: Net losses of $3.47 million and $1.45 million for nine months ended September 30, 2025 and 2024
- In older filing: Accumulated deficit of approximately $22.67 million as of September 30, 2025
- In older filing: Cash position as of September 30, 2025 of approximately $3.11 million and $0.9 million at December 31, 2024
- In older filing: Funding runway into first quarter of 2026
- Reworded:
- Older: 'We are a pharmaceutical and medical device development company built around a proprietary platform technology' changed to newer: 'Turn Therapeutics is a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies'
- Older: Emphasis on PermaFusion platform as central to company identity removed; newer focuses on GX-03 as lead program
- Older: 'Hexagen' product name and formulation details removed in newer version
- Older: Overview shifted from platform technology discussion to product-specific focus on GX-03 and dermatologic conditions
- Older: Broader exploratory programs (herpes zoster, basal cell carcinoma) removed from core discussion in newer
- Older: 'intranasal vaccine platform' described as partnership program; newer describes as 'exploratory work' not part of 'primary dermatology development path'
- Notes:
- The older filing references September 30, 2025 interim financial data while newer filing references March 31, 2026 interim data, making some comparisons reflect natural progression rather than restatement
- The older and newer filings represent different reporting periods (nine months and three months respectively), which affects net loss comparisons
- The shift from prospectus-based disclosure to Annual Report on Form 10-K reference reflects transition from direct listing prospectus to regular periodic reporting
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-18. The 4 days since 2026-10-18 have not been checked yet.
Most recent open-market transaction: 2025-12-12. Based on Form 4 filings read through 2026-10-18; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about TTRX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
2 institutional 13F filers reported holding TTRX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 2
- Reported shares held 90,339
- Reported value $659,475
reported quarterly holdings change (2025-12-31 → 2026-06-30): 1 new, 1 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about TTRX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
TTRX had 268,757 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
TTRX had 0.90% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.33 days to cover at the same settlement.
- Reported short interest (shares) 268,757
- Short interest (% of shares outstanding) 0.90%
- Prior settlement (shares) 154,372
- Reported change 74.1%
- Days to cover (reported) 1.33
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Sanofi (SNY)
- Regeneron Pharmaceuticals (REGN)
- Eli Lilly (LLY)
- Pfizer (PFE)
- AbbVie (ABBV)
- Leo Pharma
- Incyte (INCY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare TTRX vs…
Turn Therapeutics Inc. is found in…
TTRX shows up in…
Frequently asked questions
What does Turn Therapeutics Inc. (TTRX) do?
Turn Therapeutics is a clinical-stage biotechnology company focused on developing non-systemic, topical immunomodulators for inflammatory skin diseases. Its lead drug candidate, GX-03, is currently in an adaptive Phase 2 clinical trial for the treatment of atopic dermatitis (eczema) and is being advanced for other indications including onychomycosis and hidradenitis suppurativa.
What sector is Turn Therapeutics Inc. (TTRX) in?
Turn Therapeutics Inc. (TTRX) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are Turn Therapeutics Inc.'s (TTRX) competitors?
Notable peers of Turn Therapeutics Inc. (TTRX) include Sanofi, Regeneron Pharmaceuticals, Eli Lilly, Pfizer and AbbVie. This peer set is informational only — not financial advice.
Is Turn Therapeutics Inc. (TTRX) overbought or oversold right now?
Turn Therapeutics Inc. (TTRX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 40, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on TTRX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.